Expression of VEGF and Microvessel Density in Patients with Multiple Myeloma: Clinical and Prognostic Significance

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2008 May 2

PMID 18449811

Citations 9

Authors

Olivera Markovic

D Marisavljevic

V Cemerikic

A Vidovic

M Perunicic

M Todorovic

I Elezovic

M colovic

Affiliations

Soon will be listed here.

Abstract

The conflicting data are reported on the clinical significance of VEGF deregulation and intensity of angiogenesis in multiple myeloma. The aim of this study was to evaluate the incidence and prognostic significance of VEGF expression and microvessel density (MVD) in multiple myeloma, as well as the relationship of their expression with selected clinical data, histological features, and proliferative activity of myeloma cells. We analyzed bone marrow biopsy specimens obtained from 59 patients with newly diagnosed multiple myeloma. Expression of VEGF and MVD was analyzed using standard immunohistochemical method (antibodies against VEGF and CD34, respectively) on B5-fixed and routinely processed paraffin-embedded bone marrow specimens. MVD was estimated by counting the number of microvessels in three "hot spots" at 400x magnification. VEGF immunoreactivity was estimated on the basis of intensity and percentage of positive plasma cells. VEGF was expressed in 47/59 (79.7%) specimens. There was no significant correlation between VEGF overexpression and age, clinical stage, the extent of osteolytic lesions, type of monoclonal protein, hemoglobin concentration, platelet count, serum concentration of creatinine, calcium, and albumins, the extent of bone marrow infiltration, histological grade, and proliferative activity index (measured with Ki-67 immunoreactivity). No significant difference was observed regarding the overall survival between VEGF-positive and VEGF-negative patients (29 vs. 34 months, P = 0.8). Median MVD was 15, ranging from 1 to 89 microvessels per three "hot spots". There was significant correlation between MVD and histological grade, the extent of bone marrow infiltration, and proliferative activity. Significant difference was observed regarding the overall survival between patients with low MVD (<15) and patients with high MVD (> or = 15) (46 vs. 22 months, P = 0.009; univariate analysis). The results of this study did not reveal clinical significance of VEGF overexpression in multiple myeloma. On the contrary, the extent of bone marrow angiogenesis is an indicator of biological potency of malignant clone and a predictor of poor survival in newly diagnosed myeloma.

Citing Articles

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth.

Gao M, Dong H, Jiang S, Chen F, Fu Y, Luo Y Oncogenesis. 2024; 13(1):21.

PMID: 38871685 PMC: 11176168. DOI: 10.1038/s41389-024-00522-5.

Evaluation of three-dimensional arterial spin labeling perfusion imaging for the pathological investigation of musculoskeletal tumors.

Xu L, Xu L, Zhu H Exp Ther Med. 2018; 15(6):5029-5034.

PMID: 29805527 PMC: 5952077. DOI: 10.3892/etm.2018.6030.

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.

Lopes-Aguiar L, Delamain M, Brito A, Lourenco G, Costa E, Oliveira G Blood Cancer J. 2017; 7(6):e580.

PMID: 28665417 PMC: 5520405. DOI: 10.1038/bcj.2017.58.

HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma.

Jurczyszyn A, Czepiel J, Biesiada G, Gdula-Argasinska J, Cibor D, Owczarek D J Cancer. 2014; 5(7):518-24.

PMID: 24963356 PMC: 4067511. DOI: 10.7150/jca.9266.

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.

Koldehoff M, Beelen D, Elmaagacli A Cancer Gene Ther. 2014; 21(7):275-82.

PMID: 24903015 DOI: 10.1038/cgt.2014.27.

References

Kumar S, Gertz M, Dispenzieri A, Lacy M, Wellik L, Fonseca R . Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004; 34(3):235-9. DOI: 10.1038/sj.bmt.1704555. View

Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F . A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003; 88(2):176-85. View

Alexandrakis M, Passam F, Dambaki C, Pappa C, Stathopoulos E . The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004; 57(8):856-60. PMC: 1770397. DOI: 10.1136/jcp.2003.013110. View

Choi J, Ahn M, Jang S, Park C, Park Y, Oh H . Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol. 2003; 76(5):460-4. DOI: 10.1007/BF02982812. View

Pratt G . Molecular aspects of multiple myeloma. Mol Pathol. 2002; 55(5):273-83. PMC: 1187254. DOI: 10.1136/mp.55.5.273. View

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

Rajkumar S, Leong T, Roche P, Fonseca R, Dispenzieri A, Lacy M . Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000; 6(8):3111-6. View

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

Ribas C, Colleoni G, Silva M, Carregoza M, Bordin J . Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol. 2004; 73(5):311-7. DOI: 10.1111/j.1600-0609.2004.00314.x. View

10.

Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I . Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000; 79(10):574-7. DOI: 10.1007/s002770000236. View

11.

Vacca A, Ribatti D . Bone marrow angiogenesis in multiple myeloma. Leukemia. 2005; 20(2):193-9. DOI: 10.1038/sj.leu.2404067. View

12.

Ahn M, Park C, Choi J, Lee W, Lee Y, Choi I . Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci. 2001; 16(1):45-50. PMC: 3054570. DOI: 10.3346/jkms.2001.16.1.45. View

13.

Sailer M, Vykoupil K, Peest D, Coldewey R, Deicher H, Georgii A . Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients. Eur J Haematol. 1995; 54(3):137-46. DOI: 10.1111/j.1600-0609.1995.tb00204.x. View

14.

Bellamy W . Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001; 28(6):551-9. DOI: 10.1016/s0093-7754(01)90023-5. View

15.

Pruneri G, Ponzoni M, Ferreri A, Decarli N, Tresoldi M, Raggi F . Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol. 2002; 118(3):817-20. DOI: 10.1046/j.1365-2141.2002.03654.x. View

16.

Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y . Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 2004; 54(5):285-94. DOI: 10.1111/j.1440-1827.2004.01622.x. View

17.

Usnarska-Zubkiewicz L, Mazur G, Wrobel T, Poreba M, Kuliczkowski K . [Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma]. Pol Arch Med Wewn. 2003; 110(1):719-24. View

18.

Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F . Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87(3):503-8. DOI: 10.1111/j.1365-2141.1994.tb08304.x. View

19.

Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H . Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica. 2003; 88(1):113-5. View

20.

Xu J, Lai R, Kinoshita T, Nakashima N, Nagasaka T . Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol. 2002; 55(7):530-4. PMC: 1769685. DOI: 10.1136/jcp.55.7.530. View